| Features: Diagnostic agent used in PET, can determine glucose metabolism | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2-Deoxyglucose (2-DG) is a glucose analog that enters cells via GLUT transporters and is phosphorylated by hexokinase to 2-DG-6-phosphate, but cannot proceed through glycolysis. This leads to glycolytic blockade, ATP depletion, ER stress, and metabolic stress signaling.It has been studied as: -A glycolysis inhibitor (Warburg-targeting strategy) -A radiosensitizer -A metabolic stress amplifier -An adjunct to pro-oxidant therapies-2-DG primarily inhibits hexokinase -2-DG-6-phosphate accumulates and inhibits hexokinase and glycolytic flux. -an inhibitor of the glycolysis enzyme hexokinase Key Pathways: 1.Glycolysis Inhibition (blocking the glycolytic pathway.) • blockade leads to energy deprivation—a mechanism of interest particularly in cancer cells that often depend on high glycolytic rates (the “Warburg effect”). • 2DG is structurally similar to glucose and is taken up into cells via glucose transporters (GLUTs). • “glycolytic blockade.” deprives the cell of ATP and glycolytic intermediates, crucial for biosynthetic functions in rapidly dividing cancer cells. 2.Impact on the Pentose Phosphate Pathway (PPP) • The inhibition of glycolysis may indirectly affect the PPP and PPP is essential for reducing equivalents (NADPH), which are needed for cell survival and proliferation. • Decreased flux through the PPP may reduce production of NADPH.(indirect) – NADPH is essential for countering oxidative stress by regenerating reduced glutathione (GSH). • Reduced NADPH levels can compromise the cell’s ability to neutralize ROS, contributing to oxidative damage. 3.Interference with N-linked Glycosylation • 2DG can disrupt N-linked glycosylation by competing with mannose in glycoprotein synthesis. • This disruption can lead to endoplasmic reticulum (ER) stress and may trigger the unfolded protein response (UPR), contributing to cancer cell apoptosis or impaired growth. • The process of ER stress itself is associated with increased ROS generation as cellular homeostatic mechanisms are overwhelmed. 4. Mitochondrial Dysfunction and ROS Generation • While the primary action of 2DG is cytosolic (glycolysis), metabolic stress caused by energy deprivation indirectly affects mitochondrial function. • Mitochondria may increase ROS production when the electron transport chain is perturbed due to altered cellular energy demands. – Elevated ROS levels can damage mitochondrial DNA, proteins, and lipids. • The resulting oxidative damage further impairs mitochondrial efficiency and may trigger intrinsic apoptotic pathways. 5. Cellular Redox Imbalance • Inhibition of glycolysis and the subsequent reduction in PPP activity limit NADPH production, a key reducing agent. • With decreased NADPH, the regeneration of antioxidants such as glutathione and thioredoxin is impaired. – Accumulation of ROS leads to oxidative stress, damaging cellular components including lipids, proteins, and nucleic acids. • Oxidative stress may sensitize cancer cells to further apoptotic signaling cascades. 6. Activation of Stress and Apoptotic Signaling Pathways • 2DG-mediated metabolic stress and ROS accumulation can activate several stress-related kinases and transcription factors, including: – AMP-activated protein kinase (AMPK): Activated by energy deprivation, AMPK may shift cellular metabolism and promote cell cycle arrest. – c-Jun N-terminal kinase (JNK): Often activated by oxidative and ER stress, JNK can promote apoptotic signaling. – p38 MAPK: Also is responsive to stress stimuli and can drive apoptosis or cell cycle changes. • These stress responses can initiate apoptosis in cancer cells, particularly if homeostatic mechanisms for dealing with ROS are overwhelmed. Understanding these detailed pathways helps explain why 2DG can preferentially affect cancer cells that rely heavily on glycolysis (the Warburg effect) while also illuminating how ROS and oxidative damage contribute to its overall antitumor efficacy. Phase I trials have explored ~45–63 mg/kg/day oral dosing, but tolerability varies and metabolic effects are dose-dependent. possible hypothetical concern of combination with Caffeic acid phenethyl ester (CAPE) is one of the main active ingredients of propolis
Time-Scale Flag (TSF): P / R / G
|
| Source: |
| Type: |
| A radiosensitizer is an agent that makes cancer cells more sensitive to the damaging effects of radiation therapy. By using a radiosensitizer, clinicians aim to enhance the effectiveness of radiation treatment by either increasing the damage incurred by tumor cells or by interfering with the cancer cells’ repair mechanisms. This can potentially allow for lower doses of radiation, reduced side effects, or improved treatment outcomes. Pathways that help Radiosensitivity: downregulating HIF-1α, increase SIRT1, Txr List of Natural Products with radiosensitizing properties: -Curcumin:modulate NF-κB, STAT3 and has been shown in preclinical studies to enhance the effects of radiation by inhibiting cell survival pathways. -Resveratrol: -EGCG: -Quercetin: -Genistein: -Parthenolide: How radiosensitizers inhibit the thioredoxin (Trx) system in cellular contexts. Notable radiosensitizers, including: -gold nanoparticles (GNPs), -gold triethylphosphine cyanide ([Au(SCN) (PEt3)]), -auranofin, ceria nanoparticles (CONPs), -curcumin and its derivatives, -piperlongamide, -indolequinone derivatives, -micheliolide, -motexafin gadolinium, and -ethane selenide selenidazole derivatives (SeDs) |
| 2327- | 2DG, | 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:19 Target#:1107 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid